Novel high affinity bivalent helically constrained peptide against cancer
AssigneeCouncil of Scientific and Industrial Research
InventorsAmlanjyoti Dhar, Shampa Mallick, Israr Ahmed, Aditya Konar, Santu Bandyopadhyay, Siddhartha Roy
Life of this patent
Estimating the term…
Abstract
The present invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.
Claims16
A novel high affinity bivalent helically constrained peptide against cancer, wherein the said peptide is represented by SEQ ID No. 4-Lysine-SEQ ID No. 4 and having the following general formula:
Dependencies are inferred from the claim text.